{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:50:02Z","timestamp":1773157802556,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.7759\/cureus.27639","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T14:50:34Z","timestamp":1659538234000},"source":"Crossref","is-referenced-by-count":5,"title":["Managing Opioid Withdrawal in an Outpatient Setting With Lofexidine or Clonidine"],"prefix":"10.7759","author":[{"given":"Jeanne","family":"Gripshover","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM National Practice Guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","author":"American Society of Addiction Medicine","year":"2020","unstructured":"American Society of Addiction Medicine. The ASAM National Practice Guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020, 14:1-91. 10.1097\/ADM.0000000000000633","journal-title":"J Addict Med"},{"key":"ref2","article-title":"Drug Misuse: Opioid Detoxification","author":"National Collaborating Centre for Mental Health (UK)","year":"2008","unstructured":"National Collaborating Centre for Mental Health (UK). Drug Misuse: Opioid Detoxification. Royal College of Psychiatrists, Great Britain (ed): The British Psychological Society & The Royal College of Psychiatrists., Leicester, UK; 2008."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery HS","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015, 23:63-75. 10.1097\/HRP.0000000000000075","journal-title":"Harv Rev Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0376-8716(98)00040-4","article-title":"Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal","volume":"50","author":"Carnwath T","year":"1998","unstructured":"Carnwath T, Hardman J. Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998, 50:251-254. 10.1016\/s0376-8716(98)00040-4","journal-title":"Drug Alcohol Depend"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(01)00178-7","article-title":"Lofexidine versus clonidine in rapid opiate detoxification","volume":"21","author":"Gerra G","year":"2001","unstructured":"Gerra G, Zaimovic A, Giusti F, Di Gennaro C, Zambelli U, Gardini S, Delsignore R. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat. 2001, 21:11-17. 10.1016\/S0740-5472(01)00178-7","journal-title":"J Subst Abuse Treat"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002024.pub5","article-title":"Alpha\u2082-adrenergic agonists for the management of opioid withdrawal","author":"Gowing L","year":"2016","unstructured":"Gowing L, Farrell M, Ali R, White JM. Alpha\u2082-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev. 2016, CD002024. 10.1002\/14651858.CD002024.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12942","article-title":"Lofexidine in combination with oral naltrexone for opioid use disorder relapse prevention: a pilot randomized, double-blind, placebo-controlled study","volume":"28","author":"Hermes G","year":"2019","unstructured":"Hermes G, Hyman SM, Fogelman N, Kosten TR, Sinha R. Lofexidine in combination with oral naltrexone for opioid use disorder relapse prevention: a pilot randomized, double-blind, placebo-controlled study. Am J Addict. 2019, 28:480-488. 10.1111\/ajad.12942","journal-title":"Am J Addict"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0376-8716(96)01316-6","article-title":"Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital","volume":"44","author":"Kahn A","year":"1997","unstructured":"Kahn A, Mumford JP, Rogers GA, Beckford H. Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend. 1997, 44:57-61. 10.1016\/s0376-8716(96)01316-6","journal-title":"Drug Alcohol Depend"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(97)00116-6","article-title":"Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal","volume":"48","author":"Lin SK","year":"1997","unstructured":"Lin SK, Strang J, Su LW, Tsai CJ, Hu WH. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997, 48:127-133. 10.1016\/S0376-8716(97)00116-6","journal-title":"Drug Alcohol Depend"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0640-8","article-title":"Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings","volume":"190","author":"Sinha R","year":"2007","unstructured":"Sinha R, Kimmerling A, Doebrick C, Kosten TR. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl). 2007, 190:569-574. 10.1007\/s00213-006-0640-8","journal-title":"Psychopharmacology (Berl)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.03.004","article-title":"Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain","volume":"47","author":"Weiss RD","year":"2014","unstructured":"Weiss RD, Potter JS, Griffin ML, et al.. Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain. J Subst Abuse Treat. 2014, 47:140-145. 10.1016\/j.jsat.2014.03.004","journal-title":"J Subst Abuse Treat"},{"key":"ref12","article-title":"LUCEMYRA\u2122 (lofexidine) tablets, for oral use","author":"US WorldMeds LLC","year":"2018","unstructured":"US WorldMeds LLC. LUCEMYRA\u2122 (lofexidine) tablets, for oral use. US WorldMeds LLC, Louisville, KY; 2018."},{"key":"ref13","article-title":"Catapres (clonidine hydrochloride). Full Prescribing Information","author":"Boehringer Ingelheim Pharmaceuticals","year":"2009","unstructured":"Boehringer Ingelheim Pharmaceuticals. Catapres (clonidine hydrochloride). Full Prescribing Information. Boehringer Ingelheim Pharmaceuticals, International GmbH, Ridgefield, CT; 2009."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2019.101001","article-title":"Differences in the receptor binding profile of lofexidine compared to clonidine","volume":"10","author":"Raffa RB","year":"2019","unstructured":"Raffa RB, Pergolizzi JV, Taylor R, James RP, Pirner M. Differences in the receptor binding profile of lofexidine compared to clonidine. Pharmacol Pharm. 2019, 10:1-10. 10.4236\/pp.2019.101001","journal-title":"Pharmacol Pharm"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2020.09.259","article-title":"Lofexidine for acute opioid withdrawal: a clinical case series","volume":"10","author":"Renfro ML","year":"2020","unstructured":"Renfro ML, Loera LJ, Tirado CF, Hill LG. Lofexidine for acute opioid withdrawal: a clinical case series. Ment Health Clin. 2020, 10:259-263. 10.9740\/mhc.2020.09.259","journal-title":"Ment Health Clin"},{"key":"ref16","article-title":"Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine","volume":"286","author":"Tao R","year":"1998","unstructured":"Tao R, Ma Z, Auerbach SB. Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine. J Pharmacol Exp Ther. 1998, 286:481-488.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114135","article-title":"Studies of binding by 2-imidazolines to human serum albumin and alpha1-acid glycoprotein by high-performance affinity chromatography","volume":"202","author":"Woolfork AG","year":"2021","unstructured":"Woolfork AG, Suh K, Weigand M, Hage DS. Studies of binding by 2-imidazolines to human serum albumin and alpha1-acid glycoprotein by high-performance affinity chromatography. J Pharm Biomed Anal. 2021, 202:114135. 10.1016\/j.jpba.2021.114135","journal-title":"J Pharm Biomed Anal"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/105228-managing-opioid-withdrawal-in-an-outpatient-setting-with-lofexidine-or-clonidine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:48Z","timestamp":1707508008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/105228-managing-opioid-withdrawal-in-an-outpatient-setting-with-lofexidine-or-clonidine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.27639","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,3]]}}}